Temozolomide and cisplatin in relapsed/refractory acute leukemia

Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia. The median number of prio...

Descripción completa

Detalles Bibliográficos
Autores principales: Seiter, Karen, Katragadda, Sreedhar, Ponce, Doris, Rasul, Muhammad, Ahmed, Nasir
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694825/
https://www.ncbi.nlm.nih.gov/pubmed/19463179
http://dx.doi.org/10.1186/1756-8722-2-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694825/
https://www.ncbi.nlm.nih.gov/pubmed/19463179
http://dx.doi.org/10.1186/1756-8722-2-21

Ejemplares similares